Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656
ALISO VIEJO, CA, March 17, 2010 - Ambry Genetics and RainDance Technologies today jointly announced at the Annual CHI Next Generation Sequencing Conference in San Diego, CA their partnership utilizing the RDT 1000 for sequence enrichment and resequencing validation. A global leader for genetic testing and next generation sequencing services, Ambry Genetics is a CLIA Certified and CAP Accredited Diagnostic and Genomic Services company providing solutions to both clinical and research clients.
"Ambry Genetics has dedicated its investments in technology for the benefit of the scientific and research community,” said Ardy Arianpour, Director of Business Development. “We are motivated to provide our Diagnostic, Genomic and Research customers with the best solutions for their projects, and the addition of RainDance’s RDT 1000 adds a sequence-enrichment offering while providing an option for customers that are in need of high-throughput targeted sequencing with a high level of coverage, completeness and speed."
Researchers can utilize RainDance Technologies RDT 1000 and Ambry Genetics Next Generation Services to either greatly reduce study time, or to improve study quality by running more samples in the same time within the same experimental budget.
"We’re pleased to partner with Ambry Genetics to provide our microdroplet PCR-based solution in conjunction with Ambry’s genetic testing and next generation sequencing services" said Chris McNary, Chief Commercial Officer of, RainDance Technologies. "PCR is the gold standard for sequence enrichment and allows for high-resolution analysis of rare genetic variations, a focus area of Ambry Genetics’ customers". Ambry is currently offering RainDance’s sequence enrichment solution and may add two new applications, Methyl-Seq and Ultra-Deep Resequencing in the second half of 2010, further enhancing their customers’ ability to understand the origins and pathways of complex diseases.
RainDance Technologies' proprietary technology platform delivers exquisite sensitivity and data quality that inspires scientists, researchers, and clinicians to rethink the way they design experiments, approach discovery, or conduct clinical diagnostics. The core RainStorm™ Technology empowers customers to conduct de novo science in an ultra-high throughput, simple, flexible, and low-cost manner. RainDance Technologies' commercial products include instruments and high-value consumables and reagents for sequence enrichment for next-generation sequencing, ultra-deep sequencing, and methylation analysis. RainDance sells directly in the U.S. and in Europe, and is building distribution networks in Europe and Asia-Pacific. RainDance Technologies, with headquarters in Lexington, Massachusetts, and a European sales office in the United Kingdom, has approximately 70 employees worldwide. For more information about RainDance Technologies, Inc., please visit www.raindancetech.com.
Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Media Contact
Mickie Henshall
Chief Marketing Officer
REALM IDx
mhenshall@realmidx.com